PRINCETON, N.J., March 21, 2011 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of drug development services to the pharmaceutical, biotechnology, generic drug and medical device industries, announces its participation at the 19th Annual Partnerships in Clinical Trials Conference in Phoenix, Arizona from March 30 to April 1. PharmaNet and industry experts will discuss pertinent industry topics, including:
Thursday March 31
Impact of Reform on Biosimilar Drug Development
Dalvir Gill, Ph.D., President, Late Stage Development, PharmaNet and Greg Skalicky, Senior Vice President, Worldwide Business Development, PharmaNet
Proactive GCP Compliance and Quality Management Systems
Jeffrey P. McMullen, CEO, PharmaNet and John W. Hubbard, Ph.D., FCP, Senior Vice President Worldwide Head, Development Operations, Pfizer
Assess the Impact of Industry Consolidation on Change Management and Your Outsourcing Operational Model
Marisa Bower, Senior Director, Business Development, PharmaNet
Outsourcing Phase IV Observational Studies: A Different Animal?
Jeffrey Trotter, Executive Vice President, Phase IV Development, PharmaNet
Friday April 1
Challenges and Opportunities in the Global Arena in Pediatric Drug Development
Philippa Smit-Marshall, MBChB, FFPM, FICR, Vice President and General Manager of Pediatrics & Medical Sciences, PharmaNet; and Diane Hoffman, Associate Director, Clinical Research Pediatric Group, Johnson & Johnson
Conference attendees can learn more about PharmaNet's capabilities by visiting booth 901 in the exhibition hall where an international team of representatives will be available to discuss PharmaNet's expertise in helping clients reach their goal of delivering safe and effective therapeutics to patients.
PharmaNet, a recognized leader of global drug